List of publications.pdf - Karo Bio AB

1. Marzioni, M., A. Torrice, S. Saccomanno, C. Rychlicki, L. Agostinelli, I.
Pierantonelli, P. Rhonnstad, L. Trozzi, T. Apelqvist, R. Gentile, C.
Candelaresi, G. Fava, R. Semeraro, A. Benedetti, E. Gaudio, A.
Franchitto, P. Onori, S. De Minicis, G. Carpino, E. Kallin, D. Alvaro, and
S. Nilsson, An oestrogen receptor beta-selective agonist exerts antineoplastic
effects in experimental intrahepatic cholangiocarcinoma.
Dig Liver Dis, 2012. 44(2): p. 134-42.
2. Yakimchuk, K., M. Iravani, M.S. Hasni, P. Rhonnstad, S. Nilsson, M.
Jondal, and S. Okret, Effect of ligand-activated estrogen receptor
beta on lymphoma growth in vitro and in vivo. Leukemia, 2011. 25(7):
p. 1103-10.
3. Nilsson, S., K.F. Koehler, and J.A. Gustafsson, Development of
subtype-selective oestrogen receptor-based therapeutics. Nat Rev
Drug Discov, 2011. 10(10): p. 778-92.
4. Nilsson, S. and J.A. Gustafsson, Estrogen receptors: therapies
targeted to receptor subtypes. Clin Pharmacol Ther, 2011. 89(1): p.
44-55.
5. Floeistrup, E., P. Goede, R. Stroemberg, and J. Malm, Synthesis of
estradiol backbone mimics via the Stille reaction using copper(II)
oxide as co-reagent. Tetrahedron Letters, 2011. 52(2): p. 209-211.
6. Ullrich, J.W., R. Morris, R.C. Bernotas, J.M. Travins, J. Jetter, R.
Unwalla, E. Quinet, P. Nambi, I. Feingold, C. Huselton, C. Enroth, A.
Wilhelmsson, A. Goos-Nilsson, and J. Wrobel, Synthesis of 4-(3-
biaryl)quinoline sulfones as potent liver X receptor agonists. Bioorg
Med Chem Lett, 2010. 20(9): p. 2903-7.
7. Travins, J.M., R.C. Bernotas, D.H. Kaufman, E. Quinet, P. Nambi, I.
Feingold, C. Huselton, A. Wilhelmsson, A. Goos-Nilsson, and J. Wrobel,
1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor
agonists. Bioorg Med Chem Lett, 2010. 20(2): p. 526-30.
8. Singhaus, R.R., R.C. Bernotas, R. Steffan, E. Matelan, E. Quinet, P.
Nambi, I. Feingold, C. Huselton, A. Wilhelmsson, A. Goos-Nilsson, and J.
Wrobel, 3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X
receptor agonists. Bioorg Med Chem Lett, 2010. 20(2): p. 521-5.
9. Osterlund, M.K., Underlying mechanisms mediating the
antidepressant effects of estrogens. Biochim Biophys Acta, 2010.
1800(10): p. 1136-44.
10. Nilsson, S. and J.-Å. Gustafsson, Estrogen Receptors: Their actions
and functional roles in health and disease., in Proteins and Cell
Regulation, M. Campbell and C. Brunce, Editors. 2010, Springer. p. 91-
141.
11. Nilsson, S. and J.A. Gustafsson, Estrogen receptors: Their actions
and functional roles in health and disease., in Nuclear Receptors,
Proteins and Cell Regulation 8., C.M. Bunce and M.J. Campbell, Editors.
2010, Springer Netherlands. p. 91-141.
12. Ladenson, P.W., J.D. Kristensen, E.C. Ridgway, A.G. Olsson, B.
Carlsson, I. Klein, J.D. Baxter, and B. Angelin, Use of the thyroid
hormone analogue eprotirome in statin-treated dyslipidemia. N Engl
J Med, 2010. 362(10): p. 906-16.

13. Hu, B., R.J. Unwalla, I. Goljer, J.W. Jetter, E.M. Quinet, T.J. Berrodin,
M.D. Basso, I.B. Feingold, A.G. Nilsson, A. Wilhelmsson, M.J. Evans,
and J.E. Wrobel, Identification of phenylsulfone-substituted
quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR)
agonist. J Med Chem, 2010. 53(8): p. 3296-304.
14. Hu, B., R. Bernotas, R. Unwalla, M. Collini, E. Quinet, I. Feingold, A.
Goos-Nilsson, A. Wilhelmsson, P. Nambi, M. Evans, and J. Wrobel,
Quinoline-3-carboxamide containing sulfones as liver X receptor
(LXR) agonists with binding selectivity for LXRbeta and low bloodbrain
penetration. Bioorg Med Chem Lett, 2010. 20(2): p. 689-93.
15. Bernotas, R.C., R.R. Singhaus, D.H. Kaufman, J.M. Travins, J.W. Ullrich,
R. Unwalla, E. Quinet, M. Evans, P. Nambi, A. Olland, B. Kauppi, A.
Wilhelmsson, A. Goos-Nilsson, and J. Wrobel, 4-(3-
Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.
Bioorg Med Chem Lett, 2010. 20(1): p. 209-12.
16. Le Blanc, A.F., C. Albrecht, T. Bonn, P. Fechner, G. Proll, F. Proll, M.
Carlquist, and G. Gauglitz, A novel analytical tool for quantification of
estrogenicity in river water based on fluorescence labelled estrogen
receptor alpha. Anal Bioanal Chem, 2009. 395(6): p. 1769-76.
17. Hu, B., R. Unwalla, M. Collini, E. Quinet, I. Feingold, A. Goos-Nilsson, A.
Wihelmsson, P. Nambi, and J. Wrobel, Discovery and SAR of
cinnolines/quinolines as liver X receptor (LXR) agonists with
binding selectivity for LXRbeta. Bioorg Med Chem, 2009. 17(10): p.
3519-27.
18. Fechner, P., F. Proll, M. Carlquist, and G. Proll, An advanced
biosensor for the prediction of estrogenic effects of endocrinedisrupting
chemicals on the estrogen receptor alpha. Anal Bioanal
Chem, 2009. 393(6-7): p. 1579-85.
19. Bladh, L.G., K. Johansson-Haque, I. Rafter, S. Nilsson, and S. Okret,
Inhibition of extracellular signal-regulated kinase (ERK) signaling
participates in repression of nuclear factor (NF)-kappaB activity by
glucocorticoids. Biochim Biophys Acta, 2009. 1793(3): p. 439-46.
20. Bernotas, R.C., R.R. Singhaus, D.H. Kaufman, J. Ullrich, H. Fletcher,
3rd, E. Quinet, P. Nambi, R. Unwalla, A. Wilhelmsson, A. Goos-Nilsson,
M. Farnegardh, and J. Wrobel, Biarylether amide quinolines as liver X
receptor agonists. Bioorg Med Chem, 2009. 17(4): p. 1663-70.
21. Bernotas, R.C., D.H. Kaufman, R.R. Singhaus, J. Ullrich, R. Unwalla, E.
Quinet, P. Nambi, A. Wilhelmsson, A. Goos-Nilsson, and J. Wrobel, 4-(3-
aryloxyaryl)quinoline alcohols are liver X receptor agonists. Bioorg
Med Chem, 2009. 17(23): p. 8086-92.
22. Wrobel, J., R. Steffan, S.M. Bowen, R. Magolda, E. Matelan, R. Unwalla,
M. Basso, V. Clerin, S.J. Gardell, P. Nambi, E. Quinet, J.I. Reminick,
G.P. Vlasuk, S. Wang, I. Feingold, C. Huselton, T. Bonn, M. Farnegardh,
T. Hansson, A.G. Nilsson, A. Wilhelmsson, E. Zamaratski, and M.J.
Evans, Indazole-based liver X receptor (LXR) modulators with
maintained atherosclerotic lesion reduction activity but diminished
stimulation of hepatic triglyceride synthesis. J Med Chem, 2008.
51(22): p. 7161-8.
2 (15)

23. Martin-Santamaria, S., J.J. Rodriguez, S. de Pascual-Teresa, S. Gordon,
M. Bengtsson, I. Garrido-Laguna, B. Rubio-Viqueira, P.P. Lopez-Casas,
M. Hidalgo, B. de Pascual-Teresa, and A. Ramos, New scaffolds for
the design of selective estrogen receptor modulators. Org Biomol
Chem, 2008. 6(19): p. 3486-96.
24. Hu, B., E. Quinet, R. Unwalla, M. Collini, J. Jetter, R. Dooley, D.
Andraka, L. Nogle, D. Savio, A. Halpern, A. Goos-Nilsson, A.
Wilhelmsson, P. Nambi, and J. Wrobel, Carboxylic acid based
quinolines as liver X receptor modulators that have LXRbeta
receptor binding selectivity. Bioorg Med Chem Lett, 2008. 18(1): p. 54-
9.
25. Bryzgalova, G., S. Effendic, A. Khan, S. Rehnmark, P. Barbounis, J.
Boulet, G. Dong, R. Singh, S. Shapses, J. Malm, P. Webb, J.D. Baxter,
and G.J. Grover, Anti-obesity, anti-diabetic, and lipid lowering
effects of the thyroid receptor beta subtype selective agonist KB-
141. J Steroid Biochem Mol Biol, 2008. 111(3-5): p. 262-7.
26. Berkenstam, A., J. Kristensen, K. Mellstrom, B. Carlsson, J. Malm, S.
Rehnmark, N. Garg, C.M. Andersson, M. Rudling, F. Sjoberg, B. Angelin,
and J.D. Baxter, The thyroid hormone mimetic compound KB2115
lowers plasma LDL cholesterol and stimulates bile acid synthesis
without cardiac effects in humans. Proc Natl Acad Sci U S A, 2008.
105(2): p. 663-7.
27. Zinker, B., A. Mika, P. Nguyen, D. Wilcox, L. Ohman, T.W. von Geldern,
T. Opgenorth, and P. Jacobson, Liver-selective glucocorticoid
receptor antagonism decreases glucose production and increases
glucose disposal, ameliorating insulin resistance. Metabolism, 2007.
56(3): p. 380-7.
28. Malm, J., G.J. Grover, and M. Farnegardh, Recent advances in the
development of agonists selective for beta1-type thyroid hormone
receptor. Mini Rev Med Chem, 2007. 7(1): p. 79-86.
29. Malm, J., S. Gordon, P. Brandt, B. Carlsson, P. Agback, A. Backbro
Saeidi, and J. Sandberg, Thyroid receptor ligands. Part 7: Indirect
antagonists of the thyroid hormone receptor with improved affinity.
Bioorg Med Chem Lett, 2007. 17(7): p. 2018-21.
30. Hu, B., J. Jetter, D. Kaufman, R. Singhaus, R. Bernotas, R. Unwalla, E.
Quinet, D. Savio, A. Halpern, M. Basso, J. Keith, V. Clerin, L. Chen, Q.Y.
Liu, I. Feingold, C. Huselton, F. Azam, A. Goos-Nilsson, A. Wilhelmsson,
P. Nambi, and J. Wrobel, Further modification on phenyl acetic acid
based quinolines as liver X receptor modulators. Bioorg Med Chem,
2007. 15(10): p. 3321-33.
31. Garg, N., Y.L. Li, A.M. Garcia Collazo, C. Litten, D.E. Ryono, M. Zhang,
Y. Caringal, R.P. Brigance, W. Meng, W.N. Washburn, P. Agback, K.
Mellstrom, S. Rehnmark, M. Rahimi-Ghadim, T. Norin, M. Grynfarb, J.
Sandberg, G. Grover, and J. Malm, Thyroid receptor ligands. Part 8:
Thyromimetics derived from N-acylated-alpha-amino acid
derivatives displaying modulated pharmacological selectivity
compared with KB-141. Bioorg Med Chem Lett, 2007. 17(15): p. 4131-
4.
3 (15)

32. Backes, B.J., G.L. Hamilton, P. Nguyen, D. Wilcox, S. Fung, J. Wang, M.
Grynfarb, A. Goos-Nilsson, P.B. Jacobson, and T.W. von Geldern,
Parallel strategies for the preparation and selection of liver-targeted
glucocorticoid receptor antagonists. Bioorg Med Chem Lett, 2007.
17(1): p. 40-4.
33. Wilkening, R.R., R.W. Ratcliffe, E.C. Tynebor, K.J. Wildonger, A.K. Fried,
M.L. Hammond, R.T. Mosley, P.M. Fitzgerald, N. Sharma, B.M.
McKeever, S. Nilsson, M. Carlquist, A. Thorsell, L. Locco, R. Katz, K.
Frisch, E.T. Birzin, H.A. Wilkinson, S. Mitra, S. Cai, E.C. Hayes, J.M.
Schaeffer, and S.P. Rohrer, The discovery of tetrahydrofluorenones
as a new class of estrogen receptor beta-subtype selective ligands.
Bioorg Med Chem Lett, 2006. 16(13): p. 3489-94.
34. Wilkening, R.R., R.W. Ratcliffe, A.K. Fried, D. Meng, W. Sun, L. Colwell,
S. Lambert, M. Greenlee, S. Nilsson, A. Thorsell, M. Mojena, C. Tudela,
K. Frisch, W. Chan, E.T. Birzin, S.P. Rohrer, and M.L. Hammond,
Estrogen receptor beta-subtype selective tetrahydrofluorenones:
use of a fused pyrazole as a phenol bioisostere. Bioorg Med Chem
Lett, 2006. 16(15): p. 3896-901.
35. Roelens, F., N. Heldring, W. Dhooge, M. Bengtsson, F. Comhaire, J.A.
Gustafsson, E. Treuter, and D. De Keukeleire, Subtle side-chain
modifications of the hop phytoestrogen 8-prenylnaringenin result in
distinct agonist/antagonist activity profiles for estrogen receptors
alpha and beta. J Med Chem, 2006. 49(25): p. 7357-65.
36. Richards, S.J., T.W. von Geldern, P. Jacobson, D. Wilcox, P. Nguyen, L.
Ohman, M. Osterlund, B. Gelius, M. Grynfarb, A. Goos-Nilsson, J. Wang,
S. Fung, and M. Kalmanovich, Synthesis and activity of novel bileacid
conjugated glucocorticoid receptor antagonists. Bioorg Med
Chem Lett, 2006. 16(23): p. 6086-90.
37. Parker, D.L., Jr., D. Meng, R.W. Ratcliffe, R.R. Wilkening, D.M.
Sperbeck, M.L. Greenlee, L.F. Colwell, S. Lambert, E.T. Birzin, K. Frisch,
S.P. Rohrer, S. Nilsson, A.G. Thorsell, and M.L. Hammond, Triazolotetrahydrofluorenones
as selective estrogen receptor beta agonists.
Bioorg Med Chem Lett, 2006. 16(17): p. 4652-6.
38. Li, Y.L., C. Litten, K.F. Koehler, K. Mellstrom, N. Garg, A.M. Garcia
Collazo, M. Farnegard, M. Grynfarb, B. Husman, J. Sandberg, and J.
Malm, Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands
selective for the thyroid hormone receptor beta. Bioorg Med Chem
Lett, 2006. 16(4): p. 884-6.
39. Koehler, K., S. Gordon, P. Brandt, B. Carlsson, A. Backsbro-Saeidi, T.
Apelqvist, P. Agback, G.J. Grover, W. Nelson, M. Grynfarb, M.
Farnegardh, S. Rehnmark, and J. Malm, Thyroid receptor ligands. 6. A
high affinity "direct antagonist" selective for the thyroid hormone
receptor. J Med Chem, 2006. 49(23): p. 6635-7.
40. Hu, B., M. Collini, R. Unwalla, C. Miller, R. Singhaus, E. Quinet, D. Savio,
A. Halpern, M. Basso, J. Keith, V. Clerin, L. Chen, C. Resmini, Q.Y. Liu,
I. Feingold, C. Huselton, F. Azam, M. Farnegardh, C. Enroth, T. Bonn, A.
Goos-Nilsson, A. Wilhelmsson, P. Nambi, and J. Wrobel, Discovery of
phenyl acetic acid substituted quinolines as novel liver X receptor
4 (15)

agonists for the treatment of atherosclerosis. J Med Chem, 2006.
49(21): p. 6151-4.
41. Garcia Collazo, A.M., K.F. Koehler, N. Garg, M. Farnegardh, B. Husman,
L. Ye, J. Ljunggren, K. Mellstrom, J. Sandberg, M. Grynfarb, H. Ahola,
and J. Malm, Thyroid receptor ligands. Part 5: novel bicyclic agonist
ligands selective for the thyroid hormone receptor beta. Bioorg Med
Chem Lett, 2006. 16(5): p. 1240-4.
42. Carlsson, P., S. Burendahl, and L. Nilsson, Unbinding of retinoic acid
from the retinoic acid receptor by random expulsion molecular
dynamics. Biophys J, 2006. 91(9): p. 3151-61.
43. Calles, K., I. Svensson, E. Lindskog, and L. Haggstrom, Effects of
conditioned medium factors and passage number on Sf9 cell
physiology and productivity. Biotechnol Prog, 2006. 22(2): p. 394-400.
44. Calles, K., U. Eriksson, and L. Haggstrom, Effect of conditioned
medium factors on productivity and cell physiology in Trichoplusia
ni insect cell cultures. Biotechnol Prog, 2006. 22(3): p. 653-9.
45. Bryzgalova, G., H. Gao, B. Ahren, J.R. Zierath, D. Galuska, T.L. Steiler,
K. Dahlman-Wright, S. Nilsson, J.A. Gustafsson, S. Efendic, and A.
Khan, Evidence that oestrogen receptor-alpha plays an important
role in the regulation of glucose homeostasis in mice: insulin
sensitivity in the liver. Diabetologia, 2006. 49(3): p. 588-97.
46. Zhao, C., G. Toresson, L. Xu, K.F. Koehler, J.A. Gustafsson, and K.
Dahlman-Wright, Mouse estrogen receptor beta isoforms exhibit
differences in ligand selectivity and coactivator recruitment.
Biochemistry, 2005. 44(22): p. 7936-44.
47. Svensson, I., K. Calles, E. Lindskog, H. Henriksson, U. Eriksson, and L.
Haggstrom, Antimicrobial activity of conditioned medium fractions
from Spodoptera frugiperda Sf9 and Trichoplusia ni Hi5 insect cells.
Appl Microbiol Biotechnol, 2005. 69(1): p. 92-8.
48. Smirnova, J., L. Engman, C.M. Andersson, and J. Malm, An Organoiron
Approach to Thyroid Hormone Analogues. J. Organomet. Chem.,
2005. 690: p. 1784-1793.
49. Ruda, M., N. Kann, S. Gordon, J. Bergman, W. Nelson, P. Agback, L.
Hagberg, and K.F. Koehler, Solid-phase synthesis of a 6-
phenylquinolin-2(1H)-one library directed toward nuclear hormone
receptors. J Comb Chem, 2005. 7(4): p. 567-73.
50. Osterlund, M.K., M.R. Witt, and J.A. Gustafsson, Estrogen action in
mood and neurodegenerative disorders: estrogenic compounds
with selective properties-the next generation of therapeutics.
Endocrine, 2005. 28(3): p. 235-42.
51. Nilsson, S. and K.F. Koehler, Oestrogen receptors and selective
oestrogen receptor modulators: molecular and cellular
pharmacology. Basic Clin Pharmacol Toxicol, 2005. 96(1): p. 15-25.
52. Link, J.T., B. Sorensen, J. Patel, M. Grynfarb, A. Goos-Nilsson, J. Wang,
S. Fung, D. Wilcox, B. Zinker, P. Nguyen, B. Hickman, J.M. Schmidt, S.
Swanson, Z. Tian, T.J. Reisch, G. Rotert, J. Du, B. Lane, T.W. von
Geldern, and P.B. Jacobson, Antidiabetic activity of passive
5 (15)

nonsteroidal glucocorticoid receptor modulators. J Med Chem,
2005. 48(16): p. 5295-304.
53. Koehler, K.F., L.A. Helguero, L.A. Haldosen, M. Warner, and J.A.
Gustafsson, Reflections on the discovery and significance of
estrogen receptor beta. Endocr Rev, 2005. 26(3): p. 465-78.
54. Jacobson, P.B., T.W. von Geldern, L. Ohman, M. Osterland, J. Wang, B.
Zinker, D. Wilcox, P.T. Nguyen, A. Mika, S. Fung, T. Fey, A. Goos-
Nilsson, M. Grynfarb, T. Barkhem, K. Marsh, D.W. Beno, B. Nga-
Nguyen, P.R. Kym, J.T. Link, N. Tu, D.S. Edgerton, A. Cherrington, S.
Efendic, B.C. Lane, and T.J. Opgenorth, Hepatic glucocorticoid
receptor antagonism is sufficient to reduce elevated hepatic
glucose output and improve glucose control in animal models of
type 2 diabetes. J Pharmacol Exp Ther, 2005. 314(1): p. 191-200.
55. Islander, U., M.C. Erlandsson, T. Chavoshi, C. Jochems, S. Moverare, S.
Nilsson, C. Ohlsson, J.A. Gustafsson, and H. Carlsten, Estren-mediated
inhibition of T lymphopoiesis is estrogen receptor-independent
whereas its suppression of T cell-mediated inflammation is
estrogen receptor-dependent. Clin Exp Immunol, 2005. 139(2): p. 210-
5.
56. Hedfors, A., T. Appelqvist, B. Carlsson, L.G. Bladh, C. Litten, P. Agback,
M. Grynfarb, K.F. Koehler, and J. Malm, Thyroid receptor ligands. 3.
Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as
indirect antagonists of the thyroid hormone receptor. J Med Chem,
2005. 48(9): p. 3114-7.
57. Grover, G.J., K. Mellstrom, and J. Malm, Development of the thyroid
hormone receptor beta-subtype agonist KB-141: a strategy for body
weight reduction and lipid lowering with minimal cardiac side
effects. Cardiovasc Drug Rev, 2005. 23(2): p. 133-48.
58. Grover, G.J. and J. Malm, Selective thyroid hormone agonista: A
strategy for treating metabolic syndrome. Drug discov Today,
Therapeutic Strategies, 2005. 2: p. 137-142.
59. Carlsson, P., K.F. Koehler, and L. Nilsson, Glucocorticoid receptor
point mutation V571M facilitates coactivator and ligand binding by
structural rearrangement and stabilization. Mol Endocrinol, 2005.
19(8): p. 1960-77.
60. Bladh, L.G., J. Liden, A. Pazirandeh, I. Rafter, K. Dahlman-Wright, S.
Nilsson, and S. Okret, Identification of target genes involved in the
antiproliferative effect of glucocorticoids reveals a role for nuclear
factor-(kappa)B repression. Mol Endocrinol, 2005. 19(3): p. 632-43.
61. Bladh, L.G., J. Liden, K. Dahlman-Wright, M. Reimers, S. Nilsson, and S.
Okret, Identification of endogenous glucocorticoid repressed genes
differentially regulated by a glucocorticoid receptor mutant able to
separate between nuclear factor-kappaB and activator protein-1
repression. Mol Pharmacol, 2005. 67(3): p. 815-26.
62. Berkenstam, A. and J.A. Gustafsson, Nuclear receptors and their
relevance to diseases related to lipid metabolism. Curr Opin
Pharmacol, 2005. 5(2): p. 171-6.
6 (15)

63. Zhao, C., L. Xu, M. Otsuki, G. Toresson, K. Koehler, Q. Pan-
Hammarstrom, L. Hammarstrom, S. Nilsson, J.A. Gustafsson, and K.
Dahlman-Wright, Identification of a functional variant of estrogen
receptor beta in an African population. Carcinogenesis, 2004. 25(11):
p. 2067-73.
64. Yazdanparast, P., B. Carlsson, A. Oikarinen, J. Risteli, and J.
Faergemann, A thyroid hormone analogue, triiodothyroacetic acid,
corrects corticosteroid-downregulated collagen synthesis. Thyroid,
2004. 14(5): p. 345-53.
65. von Geldern, T.W., N. Tu, P.R. Kym, J.T. Link, H.S. Jae, C. Lai, T.
Apelqvist, P. Rhonnstad, L. Hagberg, K. Koehler, M. Grynfarb, A. Goos-
Nilsson, J. Sandberg, M. Osterlund, T. Barkhem, M. Hoglund, J. Wang,
S. Fung, D. Wilcox, P. Nguyen, C. Jakob, C. Hutchins, M. Farnegardh, B.
Kauppi, L. Ohman, and P.B. Jacobson, Liver-selective glucocorticoid
antagonists: a novel treatment for type 2 diabetes. J Med Chem,
2004. 47(17): p. 4213-30.
66. Tu, N., J.T. Link, B.K. Sorensen, M. Emery, M. Grynfarb, A. Goos-
Nilsson, and B. Nguyen, Bile acid conjugates of a nonsteroidal
glucocorticoid receptor modulator. Bioorg Med Chem Lett, 2004.
14(16): p. 4179-83.
67. Toresson, G., G.U. Schuster, K.R. Steffensen, M. Bengtsson, J.
Ljunggren, K. Dahlman-Wright, and J.A. Gustafsson, Purification of
functional full-length liver X receptor beta produced in Escherichia
coli. Protein Expr Purif, 2004. 35(2): p. 190-8.
68. Sandler, B., P. Webb, J.W. Apriletti, B.R. Huber, M. Togashi, S.T. Cunha
Lima, S. Juric, S. Nilsson, R. Wagner, R.J. Fletterick, and J.D. Baxter,
Thyroxine-thyroid hormone receptor interactions. J Biol Chem, 2004.
279(53): p. 55801-8.
69. Malm, J., Therapeutic thyroid hormone ligand patents 1998-2003.
Expert Opin. Ther. Patents, 2004. 14: p. 1169-1183.
70. Malm, J., Thyroid hormone ligands and metabolic diseases. Curr
Pharm Des, 2004. 10(28): p. 3525-32.
71. Link, J.T., B.K. Sorensen, J. Patel, M. Emery, M. Grynfarb, and A. Goos-
Nilsson, Discovery of novel nonsteroidal glucocorticoid receptor
modulators. Bioorg Med Chem Lett, 2004. 14(9): p. 2209-12.
72. Link, J.T., B.K. Sorensen, J. Patel, D. Arendsen, G. Li, S. Swanson, B.
Nguyen, M. Emery, M. Grynfarb, and A. Goos-Nilsson, Optimization
and metabolic stabilization of a class of nonsteroidal glucocorticoid
modulators. Bioorg Med Chem Lett, 2004. 14(16): p. 4169-72.
73. Link, J.T., B.K. Sorensen, C. Lai, J. Wang, S. Fung, D. Deng, M. Emery,
S. Carroll, M. Grynfarb, A. Goos-Nilsson, and T. Von Geldern,
Synthesis, activity, metabolic stability, and pharmacokinetics of
glucocorticoid receptor modulator-statin hybrids. Bioorg Med Chem
Lett, 2004. 14(16): p. 4173-8.
74. Hur, E., S.J. Pfaff, E.S. Payne, H. Gron, B.M. Buehrer, and R.J.
Fletterick, Recognition and accommodation at the androgen
receptor coactivator binding interface. PLoS Biol, 2004. 2(9): p. E274.
7 (15)

75. Hirschberg, D., T. Jagerbrink, J. Samskog, M. Gustafsson, M. Stahlberg,
G. Alvelius, B. Husman, M. Carlquist, H. Jornvall, and T. Bergman,
Detection of phosphorylated peptides in proteomic analyses using
microfluidic compact disk technology. Anal Chem, 2004. 76(19): p.
5864-71.
76. Hangeland, J.J., A.M. Doweyko, T. Dejneka, T.J. Friends, P. Devasthale,
K. Mellstrom, J. Sandberg, M. Grynfarb, J.S. Sack, H. Einspahr, M.
Farnegardh, B. Husman, J. Ljunggren, K. Koehler, C. Sheppard, J.
Malm, and D.E. Ryono, Thyroid receptor ligands. Part 2:
Thyromimetics with improved selectivity for the thyroid hormone
receptor beta. Bioorg Med Chem Lett, 2004. 14(13): p. 3549-53.
77. Bjornstrom, L. and M. Sjoberg, Estrogen receptor-dependent
activation of AP-1 via non-genomic signalling. Nucl Recept, 2004.
2(1): p. 3.
78. Berkenstam, A., M. Farnegardh, and J.A. Gustafsson, Convergence of
lipid homeostasis through liver X and thyroid hormone receptors.
Mech Ageing Dev, 2004. 125(10-11): p. 707-17.
79. Barkhem, T., S. Nilsson, and J.A. Gustafsson, Molecular mechanisms,
physiological consequences and pharmacological implications of
estrogen receptor action. Am J Pharmacogenomics, 2004. 4(1): p. 19-
28.
80. Ashraf, S.S., R.E. Benson, E.S. Payne, C.M. Halbleib, and H. Gron, A
novel multi-affinity tag system to produce high levels of soluble and
biotinylated proteins in Escherichia coli. Protein Expr Purif, 2004.
33(2): p. 238-45.
81. Ye, L., Y.L. Li, K. Mellstrom, C. Mellin, L.G. Bladh, K. Koehler, N. Garg,
A.M. Garcia Collazo, C. Litten, B. Husman, K. Persson, J. Ljunggren, G.
Grover, P.G. Sleph, R. George, and J. Malm, Thyroid receptor ligands.
1. Agonist ligands selective for the thyroid receptor beta1. J Med
Chem, 2003. 46(9): p. 1580-8.
82. Warner, M., L. Wang, Z. Weihua, G. Cheng, H. Sakaguchi, S. Saji, S.
Nilsson, T. Kiesselbach, and J.A. Gustafsson, Analysis of estrogen
receptor expression in tissues. Methods Enzymol, 2003. 364: p. 448-
63.
83. Sorensen, B.K., J.T. Link, T. von Geldern, M. Emery, J. Wang, B.
Hickman, M. Grynfarb, A. Goos-Nilsson, and S. Carroll, An evaluation
of a C-glucuronide as a liver targeting group: conjugate of a
glucocorticoid antagonist. Bioorg Med Chem Lett, 2003. 13(14): p.
2307-10.
84. Moverare, S., J. Dahllund, N. Andersson, U. Islander, H. Carlsten, J.A.
Gustafsson, S. Nilsson, and C. Ohlsson, Estren is a selective estrogen
receptor modulator with transcriptional activity. Mol Pharmacol,
2003. 64(6): p. 1428-33.
85. Kauppi, B., C. Jakob, M. Farnegardh, J. Yang, H. Ahola, M. Alarcon, K.
Calles, O. Engstrom, J. Harlan, S. Muchmore, A.K. Ramqvist, S. Thorell,
L. Ohman, J. Greer, J.A. Gustafsson, J. Carlstedt-Duke, and M.
Carlquist, The three-dimensional structures of antagonistic and
agonistic forms of the glucocorticoid receptor ligand-binding
8 (15)

domain: RU-486 induces a transconformation that leads to active
antagonism. J Biol Chem, 2003. 278(25): p. 22748-54.
86. Grover, G.J., K. Mellstrom, L. Ye, J. Malm, Y.L. Li, L.G. Bladh, P.G.
Sleph, M.A. Smith, R. George, B. Vennstrom, K. Mookhtiar, R. Horvath,
J. Speelman, D. Egan, and J.D. Baxter, Selective thyroid hormone
receptor-beta activation: a strategy for reduction of weight,
cholesterol, and lipoprotein (a) with reduced cardiovascular liability.
Proc Natl Acad Sci U S A, 2003. 100(17): p. 10067-72.
87. Gottlin, E.B., R.E. Benson, S. Conary, B. Antonio, K. Duke, E.S. Payne,
S.S. Ashraf, and D.J. Christensen, High-throughput screen for
inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase by
surrogate ligand competition. J Biomol Screen, 2003. 8(3): p. 332-9.
88. Farnegardh, M., T. Bonn, S. Sun, J. Ljunggren, H. Ahola, A.
Wilhelmsson, J.A. Gustafsson, and M. Carlquist, The three-dimensional
structure of the liver X receptor beta reveals a flexible ligandbinding
pocket that can accommodate fundamentally different
ligands. J Biol Chem, 2003. 278(40): p. 38821-8.
89. Benson, R.E., E.B. Gottlin, D.J. Christensen, and P.T. Hamilton,
Intracellular expression of Peptide fusions for demonstration of
protein essentiality in bacteria. Antimicrob Agents Chemother, 2003.
47(9): p. 2875-81.
90. Ashraf, S.S., E. Anderson, K. Duke, P.T. Hamilton, and Z. Fredericks,
Identification and characterization of peptide probes directed
against PKCalpha conformations. J Pept Res, 2003. 61(5): p. 263-73.
91. Alheim, K., J. Corness, M.K. Samuelsson, L.G. Bladh, T. Murata, T.
Nilsson, and S. Okret, Identification of a functional glucocorticoid
response element in the promoter of the cyclin-dependent kinase
inhibitor p57Kip2. J Mol Endocrinol, 2003. 30(3): p. 359-68.
92. Wilkinson, H.A., J. Dahllund, H. Liu, J. Yudkovitz, S.J. Cai, S. Nilsson,
J.M. Schaeffer, and S.W. Mitra, Identification and characterization of
a functionally distinct form of human estrogen receptor beta.
Endocrinology, 2002. 143(4): p. 1558-61.
93. Webb, P., N.H. Nguyen, G. Chiellini, H.A. Yoshihara, S.T. Cunha Lima,
J.W. Apriletti, R.C. Ribeiro, A. Marimuthu, B.L. West, P. Goede, K.
Mellstrom, S. Nilsson, P.J. Kushner, R.J. Fletterick, T.S. Scanlan, and
J.D. Baxter, Design of thyroid hormone receptor antagonists from
first principles. J Steroid Biochem Mol Biol, 2002. 83(1-5): p. 59-73.
94. Ruda, M.C., J. Bergman, and J. Wu, Preparation of N-alkylated
pyridones via selective N-alkylation of 2-alkoxypyridines on solid
phase. J Comb Chem, 2002. 4(5): p. 530-5.
95. Nilsson, S. and J.-Å. Gustafsson, Structure and function of the
estrogen receptor, in Contemporary endocrinology: Selective estrogen
receptor modulators: Research and clinical applications, A. Manni and
M.F. Verderame, Editors. 2002, Humana press: Totowa, NJ.
96. Nilsson, S. and J.A. Gustafsson, Biological role of estrogen and
estrogen receptors. Crit Rev Biochem Mol Biol, 2002. 37(1): p. 1-28.
97. Nilsson, S. and J.A. Gustafsson, Estrogen receptor action. Crit Rev
Eukaryot Gene Expr, 2002. 12(4): p. 237-57.
9 (15)

98. Erlandsson, A.C., L.G. Bladh, P. Stierna, T. Yucel-Lindberg, O.
Hammarsten, T. Modeer, J. Harmenberg, and A.C. Wikstrom, Herpes
simplex virus type 1 infection and glucocorticoid treatment regulate
viral yield, glucocorticoid receptor and NF-kappaB levels. J
Endocrinol, 2002. 175(1): p. 165-76.
99. Carlsson, B., B.N. Singh, M. Temciuc, S. Nilsson, Y.L. Li, C. Mellin, and
J. Malm, Synthesis and preliminary characterization of a novel
antiarrhythmic compound (KB130015) with an improved toxicity
profile compared with amiodarone. J Med Chem, 2002. 45(3): p. 623-
30.
100. Baxter, J.D., P. Goede, J.W. Apriletti, B.L. West, W. Feng, K. Mellstrom,
R.J. Fletterick, R.L. Wagner, P.J. Kushner, R.C. Ribeiro, P. Webb, T.S.
Scanlan, and S. Nilsson, Structure-based design and synthesis of a
thyroid hormone receptor (TR) antagonist. Endocrinology, 2002.
143(2): p. 517-24.
101. Barkhem, T., L.A. Haldosen, J.A. Gustafsson, and S. Nilsson, pS2 Gene
expression in HepG2 cells: complex regulation through crosstalk
between the estrogen receptor alpha, an estrogen-responsive
element, and the activator protein 1 response element. Mol
Pharmacol, 2002. 61(6): p. 1273-83.
102. Barkhem, T., L.A. Haldosen, J.A. Gustafsson, and S. Nilsson,
Transcriptional synergism on the pS2 gene promoter between a
p160 coactivator and estrogen receptor-alpha depends on the
coactivator subtype, the type of estrogen response element, and
the promoter context. Mol Endocrinol, 2002. 16(11): p. 2571-81.
103. Weihua, Z., S. Makela, L.C. Andersson, S. Salmi, S. Saji, J.I. Webster,
E.V. Jensen, S. Nilsson, M. Warner, and J.A. Gustafsson, A role for
estrogen receptor beta in the regulation of growth of the ventral
prostate. Proc Natl Acad Sci U S A, 2001. 98(11): p. 6330-5.
104. Pike, A.C., A.M. Brzozowski, J. Walton, R.E. Hubbard, A.G. Thorsell,
Y.L. Li, J.A. Gustafsson, and M. Carlquist, Structural insights into the
mode of action of a pure antiestrogen. Structure, 2001. 9(2): p. 145-
53.
105. Osterlund, M.K. and Y.L. Hurd, Estrogen receptors in the human
forebrain and the relation to neuropsychiatric disorders. Prog
Neurobiol, 2001. 64(3): p. 251-67.
106. Nilsson, S., S. Makela, E. Treuter, M. Tujague, J. Thomsen, G.
Andersson, E. Enmark, K. Pettersson, M. Warner, and J.A. Gustafsson,
Mechanisms of estrogen action. Physiol Rev, 2001. 81(4): p. 1535-65.
107. Christensen, D.J., E.B. Gottlin, R.E. Benson, and P.T. Hamilton, Phage
display for target-based antibacterial drug discovery. Drug Discov
Today, 2001. 6(14): p. 721-727.
108. Bian, Z., S. Nilsson, and J.A. Gustafsson, Selective estrogen receptor
modulators and coronary heart disease. Trends Cardiovasc Med,
2001. 11(5): p. 196-202.
109. Saji, S., E.V. Jensen, S. Nilsson, T. Rylander, M. Warner, and J.A.
Gustafsson, Estrogen receptors alpha and beta in the rodent
mammary gland. Proc Natl Acad Sci U S A, 2000. 97(1): p. 337-42.
10 (15)

110. Pike, A.C., A.M. Brzozowski, J. Walton, R.E. Hubbard, T. Bonn, J.A.
Gustafsson, and M. Carlquist, Structural aspects of agonism and
antagonism in the oestrogen receptor. Biochem Soc Trans, 2000.
28(4): p. 396-400.
111. Nilsson, S. and J.A. Gustafsson, Estrogen receptor transcription and
transactivation: Basic aspects of estrogen action. Breast Cancer
Res, 2000. 2(5): p. 360-6.
112. Johansson, L., A. Bavner, J.S. Thomsen, M. Farnegardh, J.A.
Gustafsson, and E. Treuter, The orphan nuclear receptor SHP utilizes
conserved LXXLL-related motifs for interactions with ligandactivated
estrogen receptors. Mol Cell Biol, 2000. 20(4): p. 1124-33.
113. Hubbard, R.E., A.C. Pike, A.M. Brzozowski, J. Walton, T. Bonn, J.A.
Gustafsson, and M. Carlquist, Structural insights into the
mechanisms of agonism and antagonism in oestrogen receptor
isoforms. Eur J Cancer, 2000. 36 Suppl 4: p. S17-8.
114. Grön, H. and R. Hyde-DeRuyscher, Peptides as tools in drug
discovery. Current Opinions in Drug Discovery, 2000. 3(5): p. 636-645.
115. Gron, H. and R. Hyde-Deruyscher, Peptides as tools in drug
discovery. Curr Opin Drug Discov Devel, 2000. 3(5): p. 636-45.
116. Yucel-Lindberg, T., S. Nilsson, and T. Modeer, Signal transduction
pathways involved in the synergistic stimulation of prostaglandin
production by interleukin-1beta and tumor necrosis factor alpha in
human gingival fibroblasts. J Dent Res, 1999. 78(1): p. 61-8.
117. Wijayaratne, A.L., S.C. Nagel, L.A. Paige, D.J. Christensen, J.D. Norris,
D.M. Fowlkes, and D.P. McDonnell, Comparative analyses of
mechanistic differences among antiestrogens. Endocrinology, 1999.
140(12): p. 5828-40.
118. Webb, P., P. Nguyen, C. Valentine, G.N. Lopez, G.R. Kwok, E.
McInerney, B.S. Katzenellenbogen, E. Enmark, J.A. Gustafsson, S.
Nilsson, and P.J. Kushner, The estrogen receptor enhances AP-1
activity by two distinct mechanisms with different requirements for
receptor transactivation functions. Mol Endocrinol, 1999. 13(10): p.
1672-85.
119. Warner, M., S. Nilsson, and J.A. Gustafsson, The estrogen receptor
family. Curr Opin Obstet Gynecol, 1999. 11(3): p. 249-54.
120. Pike, A.C., A.M. Brzozowski, R.E. Hubbard, T. Bonn, A.G. Thorsell, O.
Engstrom, J. Ljunggren, J.A. Gustafsson, and M. Carlquist, Structure of
the ligand-binding domain of oestrogen receptor beta in the
presence of a partial agonist and a full antagonist. EMBO J, 1999.
18(17): p. 4608-18.
121. Paige, L.A., D.J. Christensen, H. Gron, J.D. Norris, E.B. Gottlin, K.M.
Padilla, C.Y. Chang, L.M. Ballas, P.T. Hamilton, D.P. McDonnell, and
D.M. Fowlkes, Estrogen receptor (ER) modulators each induce
distinct conformational changes in ER alpha and ER beta. Proc Natl
Acad Sci U S A, 1999. 96(7): p. 3999-4004.
122. Norris, J.D., L.A. Paige, D.J. Christensen, C.Y. Chang, M.R. Huacani, D.
Fan, P.T. Hamilton, D.M. Fowlkes, and D.P. McDonnell, Peptide
11 (15)

antagonists of the human estrogen receptor. Science, 1999.
285(5428): p. 744-6.
123. Jonsson, A.P., M. Carlquist, B. Husman, J. Ljunggren, H. Jornvall, T.
Bergman, and W.J. Griffiths, Structural analysis of the thyroid
hormone receptor ligand binding domain: studies using a
quadrupole time-of-flight tandem mass spectrometer. Rapid
Commun Mass Spectrom, 1999. 13(18): p. 1782-91.
124. Chang, C., J.D. Norris, H. Gron, L.A. Paige, P.T. Hamilton, D.J. Kenan,
D. Fowlkes, and D.P. McDonnell, Dissection of the LXXLL nuclear
receptor-coactivator interaction motif using combinatorial peptide
libraries: discovery of peptide antagonists of estrogen receptors
alpha and beta. Mol Cell Biol, 1999. 19(12): p. 8226-39.
125. Ribeiro, R.C., J.W. Apriletti, R.L. Wagner, B.L. West, W. Feng, R. Huber,
P.J. Kushner, S. Nilsson, T. Scanlan, R.J. Fletterick, F. Schaufele, and
J.D. Baxter, Mechanisms of thyroid hormone action: insights from X-
ray crystallographic and functional studies. Recent Prog Horm Res,
1998. 53: p. 351-92; discussion 392-4.
126. Ribeiro, R.C., J.W. Apriletti, R.L. Wagner, W. Feng, P.J. Kushner, S.
Nilsson, T.S. Scanlan, B.L. West, R.J. Fletterick, and J.D. Baxter, X-ray
crystallographic and functional studies of thyroid hormone
receptor. J Steroid Biochem Mol Biol, 1998. 65(1-6): p. 133-41.
127. Nilsson, S., G.G. Kuiper, and J.-Å. Gustafsson, ERbeta: a novel
estrogen receptor offers the potential for new drug development.
Trends Endocrinol Metab, 1998. 9: p. 387-395.
128. Kuiper, G.G., S. Nilsson, and J.-Å. Gustafsson, Cloning, expression
and function of a novel estrogen receptor, in Estrogens and the
vessel wall, G.M. Rubanyi and R.F. Kauffman, Editors. 1998, Harwood
academic publishers: London. p. 1-17.
129. Kuiper, G.G., S. Nilsson, and J.-Å. Gustafsson, Characteristics and
function of the noval estrogen receptor beta, in Hormones and
signalling, B.W. O´Malley, Editor. 1998, Academic press inc.: San Diego,
CA. p. 90-112.
130. Kuiper, G.G., M. Carlquist, and J.A. Gustafsson, Estrogen is a male
and female hormone. Science & Medicine, 1998. 5(4): p. 36-45.
131. Kay, B.K., A.V. Kurakin, and R. Hyde-DeRuyscher, From peptides to
drugs via phage display. Drug Discovery Today, 1998. 8: p. 370-378.
132. Johansson, M., S. Nilsson, and B.O. Lund, Interactions between
methylsulfonyl PCBs and the glucocorticoid receptor. Environ Health
Perspect, 1998. 106(12): p. 769-72.
133. Huang, C.J., D. Feltkamp, S. Nilsson, and J.A. Gustafsson, Synergistic
activation of RLD-1 by agents triggering PKA and PKC dependent
signalling. Biochem Biophys Res Commun, 1998. 243(3): p. 657-63.
134. Greenidge, P.A., B. Carlsson, L.G. Bladh, and M. Gillner,
Pharmacophores incorporating numerous excluded volumes
defined by X-ray crystallographic structure in three-dimensional
database searching: application to the thyroid hormone receptor. J
Med Chem, 1998. 41(14): p. 2503-12.
12 (15)

135. Barkhem, T., B. Carlsson, Y. Nilsson, E. Enmark, J. Gustafsson, and S.
Nilsson, Differential response of estrogen receptor alpha and
estrogen receptor beta to partial estrogen agonists/antagonists. Mol
Pharmacol, 1998. 54(1): p. 105-12.
136. Apriletti, J.W., R.C. Ribeiro, R.L. Wagner, W. Feng, P. Webb, P.J.
Kushner, B.L. West, S. Nilsson, T.S. Scanlan, R.J. Fletterick, and J.D.
Baxter, Molecular and structural biology of thyroid hormone
receptors. Clin Exp Pharmacol Physiol Suppl, 1998. 25: p. S2-11.
137. Witkowska, H.E., M. Carlquist, O. Engstrom, B. Carlsson, T. Bonn, J.A.
Gustafsson, and C.H. Shackleton, Characterization of bacterially
expressed rat estrogen receptor beta ligand binding domain by
mass spectrometry: structural comparison with estrogen receptor
alpha. Steroids, 1997. 62(8-9): p. 621-31.
138. Paech, K., P. Webb, G.G. Kuiper, S. Nilsson, J. Gustafsson, P.J.
Kushner, and T.S. Scanlan, Differential ligand activation of estrogen
receptors ERalpha and ERbeta at AP1 sites. Science, 1997.
277(5331): p. 1508-10.
139. Nilsson, S. and J.A. Gustafsson, [New glucocorticoids are more
selective. Current knowledge can eliminate serious adverse
effects]. Lakartidningen, 1997. 94(26-27): p. 2465-71.
140. Kuiper, G.G., B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, S.
Nilsson, and J.A. Gustafsson, Comparison of the ligand binding
specificity and transcript tissue distribution of estrogen receptors
alpha and beta. Endocrinology, 1997. 138(3): p. 863-70.
141. Carlsson, B., H. Ahola, and J. Haggblad, Application of a novel
method for the comparison of DNA binding parameters of the two
human thyroid hormone receptor subtypes hTR alpha 1 and hTR
beta 1. J Recept Signal Transduct Res, 1997. 17(1-3): p. 355-71.
142. Brzozowski, A.M., A.C. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O.
Engstrom, L. Ohman, G.L. Greene, J.A. Gustafsson, and M. Carlquist,
Molecular basis of agonism and antagonism in the oestrogen
receptor. Nature, 1997. 389(6652): p. 753-8.
143. Barkhem, T., C. Andersson-Ross, M. Hoglund, and S. Nilsson,
Characterization of the "estrogenicity" of tamoxifen and raloxifene
in HepG2 cells: regulation of gene expression from an ERE
controlled reporter vector versus regulation of the endogenous
SHBG and PS2 genes. J Steroid Biochem Mol Biol, 1997. 62(1): p. 53-
64.
144. Witkowska, H.E., B.N. Green, M. Carlquist, and C.H. Shackleton, Intact
noncovalent dimer of estrogen receptor ligand-binding domain can
be detected by electrospray ionization mass spectrometry. Steroids,
1996. 61(7): p. 433-8.
145. Sylven, C., E. Jansson, P. Sotonyi, F. Waagstein, T. Barkhem, and M.
Bronnegard, Cardiac nuclear hormone receptor mRNA in heart
failure in man. Life Sci, 1996. 59(22): p. 1917-22.
146. Salerno, A.J., Z. He, A. Goos-Nilsson, H. Ahola, and P. Mak, Differential
transcriptional regulation of the apoAI gene by retinoic acid
13 (15)

eceptor homo- and heterodimers in yeast. Nucleic Acids Res, 1996.
24(4): p. 566-72.
147. Kuiper, G.G., E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.A.
Gustafsson, Cloning of a novel receptor expressed in rat prostate
and ovary. Proc Natl Acad Sci U S A, 1996. 93(12): p. 5925-30.
148. Hegy, G.B., C.H. Shackleton, M. Carlquist, T. Bonn, O. Engstrom, P.
Sjoholm, and H.E. Witkowska, Carboxymethylation of the human
estrogen receptor ligand-binding domain-estradiol complex:
HPLC/ESMS peptide mapping shows that cysteine 447 does not
react with iodoacetic acid. Steroids, 1996. 61(6): p. 367-73.
149. Yucel-Lindberg, T., H. Ahola, S. Nilsson, J. Carlstedt-Duke, and T.
Modeer, Interleukin-1 beta induces expression of cyclooxygenase-2
mRNA in human gingival fibroblasts. Inflammation, 1995. 19(5): p.
549-60.
150. Haggblad, J., B. Carlsson, P. Kivela, and H. Siitari, Scintillating
microtitration plates as platform for determination of [3H]estradiol
binding constants for hER-HBD. Biotechniques, 1995. 18(1): p. 146-
51.
151. Carlsson, B. and J. Haggblad, Quantitative determination of DNAbinding
parameters for the human estrogen receptor in a solidphase,
nonseparation assay. Anal Biochem, 1995. 232(2): p. 172-9.
152. Salomonsson, M., J. Haggblad, B.W. O'Malley, and G.M. Sitbon, The
human estrogen receptor hormone binding domain dimerizes
independently of ligand activation. J Steroid Biochem Mol Biol, 1994.
48(5-6): p. 447-52.
153. Salomonsson, M., B. Carlsson, and J. Haggblad, Equilibrium hormone
binding to human estrogen receptors in highly diluted cell extracts
is non-cooperative and has a Kd of approximately 10 pM. J Steroid
Biochem Mol Biol, 1994. 50(5-6): p. 313-8.
154. Zilliacus, J., A.P. Wright, U. Norinder, J.A. Gustafsson, and J. Carlstedt-
Duke, DNA-binding specificity of mutant glucocorticoid receptor
DNA-binding domains. Ann N Y Acad Sci, 1993. 684: p. 253-5.
155. Grandien, K.F., A. Berkenstam, S. Nilsson, and J.A. Gustafsson,
Localization of DNase I hypersensitive sites in the human oestrogen
receptor gene correlates with the transcriptional activity of two
differentially used promoters. J Mol Endocrinol, 1993. 10(3): p. 269-
77.
156. Dahlman-Wright, K., K. Grandien, S. Nilsson, J.A. Gustafsson, and J.
Carlstedt-Duke, Protein-protein interactions between the DNAbinding
domains of nuclear receptors: influence on DNA-binding. J
Steroid Biochem Mol Biol, 1993. 45(4): p. 239-50.
157. Banner, C.D., A. Goos-Nilsson, J. Sjovall, J.A. Gustafsson, and J.J.
Rafter, A method for characterization of endogenous ligands to
orphan receptors belonging to the steroid hormone receptor
superfamily--isolation of progesterone from pregnancy plasma
using progesterone receptor ligand-binding domain. Anal Biochem,
1992. 200(1): p. 163-70.
14 (15)

158. Ek-Rylander, B., P. Bill, M. Norgard, S. Nilsson, and G. Andersson,
Cloning, sequence, and developmental expression of a type 5,
tartrate-resistant, acid phosphatase of rat bone. J Biol Chem, 1991.
266(36): p. 24684-9.
159. Cohen, F.E., G.J. Strewler, M.S. Bradley, M. Carlquist, M. Nilsson, M.
Ericsson, T.L. Ciardelli, and R.A. Nissenson, Analogues of parathyroid
hormone modified at positions 3 and 6. Effects on receptor binding
and activation of adenylyl cyclase in kidney and bone. J Biol Chem,
1991. 266(3): p. 1997-2004.
160. Barkhem, T., B. Carlsson, J. Simons, B. Moller, A. Berkenstam, J.A.
Gustafsson, and S. Nilsson, High level expression of functional full
length human thyroid hormone receptor beta 1 in insect cells using
a recombinant baculovirus. J Steroid Biochem Mol Biol, 1991. 38(6): p.
667-75.
161. Alksnis, M., T. Barkhem, P.E. Stromstedt, H. Ahola, E. Kutoh, J.A.
Gustafsson, L. Poellinger, and S. Nilsson, High level expression of
functional full length and truncated glucocorticoid receptor in
Chinese hamster ovary cells. Demonstration of ligand-induced
down-regulation of expressed receptor mRNA and protein. J Biol
Chem, 1991. 266(16): p. 10078-85.
15 (15)